ランレオチドは,血管新生手術後の血清フリーおよび全インスリン型の成長因子Iを減少させます
J Frystyk1, C Skjaerbaek, N Alexander
1Institute of Experimental Clinical Research, Aarhus (Denmark) University Hospital, Denmark.
Circulation
|November 15, 1996
まとめ
ランレオチドによる治療は,インスリン類似成長因子I (IGF-I) を著しく低下させ,皮膚経光冠動脈血管新生手術 (PTCA) 後のIGFBP-1を増加させます. IGFシステムにおけるこれらの変更は,長期的な結果を改善する可能性があります.
科学分野:
- エンドクリノロジー エンドクリノロジー
- 心血管医学 心血管医学
- 薬理学 薬理学とは
背景:
- インスリン型の成長因子I (IGF-I) は,皮膚経光冠動脈血管形成術 (PTCA) の後の血管静止症に関与しています.
- IGFシステムに対する治療介入の影響を理解することは,PTCA後の合併症の管理に不可欠です.
研究 の 目的:
- PTCAを受けている患者の循環中のIGF-Iレベルおよび関連する要因に対するソマトスタチンアナログであるランレオチドの効果を調査する.
- ランレオチドが誘発したIGFシステムの変化が,PTCA後に改善された長期的な結果と相関するかどうかを判断する.
主な方法:
- PTCAを受けた553人の患者が参加した臨床試験です.
- 連続した皮下ランレオチド輸液の投与とプラセボの投与.
- 血清の総および自由なIGF-I,IGF-II,IGFBP-1,IGFBP-3およびインスリン濃度の測定.
主要な成果:
- ランレオチドはPTCA後の総IGF-Iを7%減らし,自由IGF-Iを22~27%減少させた.
- プラセボを投与された患者は,自由IGF-I.I.の有意な増加を示しました.
- ランレオチド治療は,IGFBP-1レベルを上昇させ,IGF-IIとIGFBP-3をわずかに低下させ,インスリンレベルは変化しなかった.
結論:
- ランレオチドは,循環中の総および自由のIGF-Iを急激に減少させ,自由のIGF-Iにより顕著な影響を及ぼします.
- ランレオチドの投与は,PTCA後のIGFBP-1レベルを上昇させる.
- ランレオチドによるIGFシステムにおける観察された変化は,PTCA後の長期的な改善に寄与する可能性がある.
関連する概念動画
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...